• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Expert Opinion

       

      Dr William Tillet – Unmet Needs in PsA

      Clinical Summary Videos

       

      RINVOQ Discovery Journey & MOA 

      SELECT PsA 2

      SELECT-PsA 1

      Downloadable Clinical Summaries

      SELECT-PSA 1

      View a summary of the SELECT-PsA 1 clinical
      trial - Trial of Upadacitinib and Adalimumab for psoriatic
      arthritis

      SELECT-PSA 2

      View a summary of the SELECT-PsA 2 clinical trial - Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

      I want to find out more about RINVOQ

      I want to receive more information about RINVOQ

      UK-UPAD-220094. Date of preparation: March 2022

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com